Share on StockTwits

Analysts at Mizuho increased their price objective on shares of Cepheid (NASDAQ:CPHD) from $50.00 to $65.00 in a research report issued to clients and investors on Friday, Analyst Ratings Network reports. The firm currently has a “buy” rating on the stock. Mizuho’s target price points to a potential upside of 22.97% from the company’s current price.

A number of other analysts have also recently weighed in on CPHD. Analysts at JPMorgan Chase & Co. downgraded shares of Cepheid from an “overweight” rating to a “neutral” rating in a research note to investors on Tuesday, January 7th. Separately, analysts at Needham & Company initiated coverage on shares of Cepheid in a research note to investors on Thursday, December 19th. They set a “hold” rating on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Cepheid in a research note to investors on Wednesday, December 18th. They set a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $46.56.

Shares of Cepheid (NASDAQ:CPHD) traded up 11.83% during mid-day trading on Friday, hitting $52.86. 2,905,624 shares of the company’s stock traded hands. Cepheid has a 52-week low of $30.95 and a 52-week high of $54.45. The stock’s 50-day moving average is $47.00 and its 200-day moving average is $40.85. The company’s market cap is $3.586 billion.

Cepheid (NASDAQ:CPHD) last issued its quarterly earnings data on Friday, January 31st. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.11) by $0.04. The company had revenue of $113.30 million for the quarter, compared to the consensus estimate of $102.17 million. Analysts expect that Cepheid will post $0.01 EPS for the current fiscal year.

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.